Nephrocare Health Services FY26 Revenue Up 32.2% to ₹998.8 Crore
Nephrocare Health Services (NEPHROPLUS) reported a 32.2% YoY increase in FY26 revenue, reaching ₹998.8 crore. Adjusted EBITDA rose 37.6% to ₹238.1 crore. Treatment volumes grew by 16.6% YoY. The company's international revenue contribution increased from 31.8% to 41.8%. Vikram Vuppala and Rohit Singh commented on the company's growth and strategic focus.
The strong financial performance and strategic initiatives outlined in the announcement indicate a potentially positive impact on the company's future prospects.
The announcement highlights significant revenue and EBITDA growth, along with strategic expansion and positive management commentary.
Nephrocare Health Services Limited (NEPHROPLUS), Asia’s largest dialysis network, announced its financial results for the fourth quarter and full year ended March 31, 2026. FY26 revenue reached ₹998.8 crore, a 32.2% increase year-over-year, while Q4 FY26 revenue was ₹265.6 crore, up 21.2% year-over-year. This growth was mainly driven by a 16.6% year-over-year increase in treatment volumes for FY26 and a favorable mix shift towards international markets, where revenue per treatment is higher. International revenue contribution rose from 31.8% in FY25 to 41.8% in FY26. Adjusted EBITDA for FY26 was ₹238.1 crore, a 37.6% increase year-over-year. Adjusted PAT for FY26 stood at ₹128.3 crore, with a RoCE (Pre-Tax) of 22.8%. The company's operational highlights include 38,44,658 treatments in FY26 and 9,96,074 treatments in Q4 FY26. The number of guests as of March 31, 2026, was 36,981.
Mr. Vikram Vuppala, Chairman & MD, commented on the results, highlighting the increasing burden of diabetes and hypertension as key risk factors for Chronic Kidney Disease and emphasized the importance of both preventing CKD and delivering quality dialysis services. He noted NephroPlus's strong position to scale, driven by its efficiency, clinical outcomes, and digital innovation, including the Reformmed.AI application. Mr Rohit Singh, Group Chief Executive Officer mentioned FY26 was an important year as NephroPlus transitioned into a publicly listed company. Mr. Prashant Goenka, Chief Financial Officer, added that the NephroPlus story has always been about balanced and disciplined growth.
What to do with a filing like this
Nephrocare Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Nephrocare Health Services Limited. Read the original for the full detail.